1823 related articles for article (PubMed ID: 31812070)
21. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
[TBL] [Abstract][Full Text] [Related]
22. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
23. The Lung Adenocarcinoma Microenvironment Mining and Its Prognostic Merit.
Zhao R; Ding D; Yu W; Zhu C; Ding Y
Technol Cancer Res Treat; 2020; 19():1533033820977547. PubMed ID: 33280515
[TBL] [Abstract][Full Text] [Related]
24. Overexpression and diagnostic significance of INTS7 in lung adenocarcinoma and its effects on tumor microenvironment.
Li X; Yao Y; Qian J; Jin G; Zeng G; Zhao H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108346. PubMed ID: 34781123
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
[No Abstract] [Full Text] [Related]
26. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
Yu L; Qiao R; Xu J; Han B; Zhong R
Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
[TBL] [Abstract][Full Text] [Related]
28. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
29. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
30. Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression.
Liu Y; Xie P; Jiang D; Liu J; Zhang J; Bian T; Shi J
Front Immunol; 2020; 11():568440. PubMed ID: 33424830
[TBL] [Abstract][Full Text] [Related]
31.
Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
[No Abstract] [Full Text] [Related]
32. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.
Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q
Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996
[TBL] [Abstract][Full Text] [Related]
33. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
34. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
35. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
[No Abstract] [Full Text] [Related]
38. P2RX7B is a new theranostic marker for lung adenocarcinoma patients.
Benzaquen J; Dit Hreich SJ; Heeke S; Juhel T; Lalvee S; Bauwens S; Saccani S; Lenormand P; Hofman V; Butori M; Leroy S; Berthet JP; Marquette CH; Hofman P; Vouret-Craviari V
Theranostics; 2020; 10(24):10849-10860. PubMed ID: 33042257
[No Abstract] [Full Text] [Related]
39. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
40. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
